In light of recent data suggesting limited activity of Atezolizumab monotherapy in the 2nd line treatment of ES-SCLC, would you still offer Atezolizumab maintenance following combination chemo-IO in the first line setting?   

The data as single agent therapy in the second line setting should not impact decisions regarding front line therapy. In IMpower133 patients randomized to chemotherapy and atezolizumab continued on atezolizumab if they had stable disease following completion of the chemotherapy plus atezolizumab. Th...